These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 30890542)

  • 21. The impact of stratifying by family history in colorectal cancer screening programs.
    Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
    Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
    Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
    J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
    Meklin J; SyrjÄnen K; Eskelinen M
    Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-colonoscopy colorectal cancer: A population-based cohort study of fecal occult blood test-positive colonoscopies.
    Denis B; Bertolaso A; Gendre I; Perrin P; Hammas K
    Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102285. PubMed ID: 38246488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme.
    Bretagne JF; Carlo A; Piette C; Rousseau C; Cosson M; Lièvre A
    Br J Cancer; 2021 Nov; 125(11):1494-1502. PubMed ID: 34511603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.
    Hillyer GC; Schmitt KM; Freedberg DE; Kramer RA; Su Y; Rosenberg RM; Neugut AI
    Am J Prev Med; 2014 Aug; 47(2):182-7. PubMed ID: 24951037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
    Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
    Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal adherence with fecal occult blood test screening in community practice.
    Fenton JJ; Elmore JG; Buist DS; Reid RJ; Tancredi DJ; Baldwin LM
    Ann Fam Med; 2010; 8(5):397-401. PubMed ID: 20843880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fecal occult blood test in colorectal cancer screening.
    Li JN; Yuan SY
    J Dig Dis; 2019 Feb; 20(2):62-64. PubMed ID: 30714325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for colorectal neoplasias with fecal occult blood tests: false-positive impact of non-dietary restriction.
    Roslani AC; Abdullah T; Arumugam K
    Asian Pac J Cancer Prev; 2012; 13(1):237-41. PubMed ID: 22502676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study.
    Levi Z; Birkenfeld S; Vilkin A; Bar-Chana M; Lifshitz I; Chared M; Maoz E; Niv Y
    Int J Cancer; 2011 May; 128(10):2415-24. PubMed ID: 20658527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.
    Goede SL; Rabeneck L; van Ballegooijen M; Zauber AG; Paszat LF; Hoch JS; Yong JH; Kroep S; Tinmouth J; Lansdorp-Vogelaar I
    PLoS One; 2017; 12(3):e0172864. PubMed ID: 28296927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme.
    Lo SH; Halloran S; Snowball J; Seaman H; Wardle J; von Wagner C
    Gut; 2015 Feb; 64(2):282-91. PubMed ID: 24812001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of follow-up colonoscopy after positive FOBT in an organized colorectal cancer screening program is associated with modifiable health care practices.
    Correia A; Rabeneck L; Baxter NN; Paszat LF; Sutradhar R; Yun L; Tinmouth J
    Prev Med; 2015 Jul; 76():115-22. PubMed ID: 25895843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening.
    van der Vlugt M; Grobbee EJ; Bossuyt PM; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Essink-Bot ML; Spaander MC; Dekker E
    Br J Cancer; 2017 Jan; 116(1):44-49. PubMed ID: 27923037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.